Showing results (161-170 of 261) with videos related to

Sort By:
Pageof 27
Scientific Reports|May 29, 2021
Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infectionAnna Prats, Ignacio Martínez-Zalacaín, Beatriz Mothe, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2005
Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL populationTonia Woodberry, Todd J Suscovich, Leah M Henry, et al.
Blood|July 2, 2002
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myelomaChristian Brander, Noopur Raje, Paula G O'Connor, et al.
Journal of Immunological Methods|April 2, 2003
Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responsesRika Draenert, Marcus Altfeld, Christian Brander, et al.
The Journal of Infectious Diseases|June 19, 2009
Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmissionLisa M Butler, Grant Dorsey, Wolfgang Hladik, et al.
International Journal of Cancer|February 10, 2010
Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt"Sheila C Dollard, Lisa M Butler, Alison M Graves Jones, et al.
AIDS (London, England)|February 28, 2008
Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicityNicole Frahm, David C Nickle, Caitlyn H Linde, et al.
The Journal of Infection|November 9, 2025
Bictegravir/emtricitabine/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial)Juan Ambrosioni, Elisa de Lazzari, Sonsoles Sánchez-Palomino, et al.
Contemporary Clinical Trials|November 11, 2025
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIVAna Gabriela Pires Dos Santos, Manal Abunimeh, Beatriz Mothe, et al.
Nature Communications|March 4, 2025
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trialLucia Bailón, José Moltó, Adrian Curran, et al.
Pageof 27